Mometasona Ratiopharm (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, altering gene transcription. This reduces the production of inflammatory cytokines and chemokines, limits immune cell infiltration, and decreases swelling and mucus production, leading to symptom relief.

The specific dose and frequency of Mometasona Ratiopharm are determined by the prescribing clinician based on the patient’s age, severity of symptoms, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks before prescribing it to pregnant or nursing women. Consultation with a physician is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Mometasona Ratiopharm contains mometasone furoate, a potent corticosteroid with high receptor affinity and low systemic bioavailability. Compared with older agents like fluticasone or budesonide, it often provides comparable efficacy at lower doses, but individual response may vary.

Store the nasal spray at room temperature, below 25 °C (77 °F). Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Mometasona Ratiopharm is a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed.

Serious risks, though rare, include adrenal suppression, increased intra‑ocular pressure leading to glaucoma or cataracts, and severe nasal septum perforation. Patients should report persistent headaches, visual changes, unusual fatigue, or nosebleeds to their healthcare provider promptly.

Individuals with a known hypersensitivity to mometasone furoate or any component of the formulation should avoid using the product. It is also contraindicated in patients with active untreated nasal infections until the infection is resolved.